Apply for a trade account

Peptide API supplier for compounding pharmacies

Short answerInternational Wholesale Peptides is a peptide API supplier for compounding pharmacies that hold a current license. It sells bulk API powder only, with a certificate of analysis per lot and a stated manufacturing origin. It does not sell finished compounded drugs, and each pharmacy must complete its own supplier qualification.

Updated · 6 min read

What we sell
Bulk peptide API powder
What we do not sell
Finished compounded drugs
Buyers
Licensed pharmacies and licensed manufacturers
Per-lot tests
Identity (MS), purity (HPLC), peptide content
Conditional tests
Endotoxin and sterility, where relevant
Origin
Stated per lot. Synthesis site named for USA-Synthesized lots

International Wholesale Peptides (IWP) is a peptide API supplier for compounding pharmacies that hold a current license. We sell bulk API powder only. We do not sell finished compounded drugs. Each lot carries a certificate of analysis that names the testing laboratory, and each pharmacy must carry out its own supplier qualification before use.

Who this page is for

This page is for pharmacists in charge, quality managers and purchasing staff at licensed compounding pharmacies, and for licensed manufacturers that buy peptide API. It is written for the United States first, with a note on other countries. It is not for clinics or prescribers, who should read the page for clinics.

What a peptide API supplier for compounding pharmacies provides

Product class Typical pack Documents with each lot
Bulk API powder, USA-Synthesized (active made in the United States; finished and tested in the United States) Sealed containers, pack size set on the quote Certificate of analysis, lot origin file naming the synthesis site, imported inputs disclosure
Bulk API powder, US-Finished (active made outside the United States, source country disclosed; finished and tested in the United States) Sealed containers, pack size set on the quote Certificate of analysis, origin statement naming the source country of the active and the finishing site
Bulk API powder, Standard (made and finished outside the United States) Sealed containers, pack size set on the quote Certificate of analysis, origin statement naming where the lot was made

Research-grade vials are not offered to pharmacies for compounding. Format details are on the bulk API powder page.

What the certificate reports

  • Identity by mass spectrometry, observed mass against theoretical mass.
  • Purity by reversed-phase HPLC, main peak area percent against a limit.
  • Peptide content, with the method named. This is the figure a pharmacist uses to correct a weighed amount of powder to the amount of peptide. Purity alone does not allow that correction.
  • Salt form. Acetate and trifluoroacetate salts have different peptide content and are not interchangeable in a formula without recalculation.
  • Bacterial endotoxin by LAL, where relevant, in endotoxin units per milligram.
  • Sterility by USP <71>, where relevant.
  • Testing laboratory, by name.

Every field is explained on the certificate of analysis page, and the certificate can be checked against the lot number through lot lookup.

The lawful route for a US compounding pharmacy

The statements below are a summary as of November 2026. They are not legal advice. A pharmacy must confirm its own position with counsel, FDA guidance and its state board.

503A and 503B are separate. A 503A pharmacy compounds for identified individual patients on a valid prescription. A 503B outsourcing facility is a separate category with its own registration and manufacturing requirements. The bulk drug substances each may use are governed by different provisions.

The draft federal policy. An HHS draft enforcement-discretion policy was published on 30 October 2026. It concerns 503A compounding of six peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. Among other conditions, it expects the API to come from an FDA-registered manufacturer and to be accompanied by a certificate of analysis that identifies the manufacturing site.

What the draft is not. It is a draft. It is not an approval of any of these substances. It does not cover 503B outsourcing facilities. Its conditions may change before it is finalized, and it may not be finalized.

Registration is not approval. FDA establishment registration is a listing. It does not approve a site, and it does not by itself prove compliance with current good manufacturing practice.

State law still applies. State boards of pharmacy set their own rules. Several have said that research-labeled product cannot be used in patient care.

The 503A and 503B peptide sourcing guide discusses these points with sources.

Other countries

Outside the United States, peptide API moves only through the route the destination country allows, normally a licensed importer or a pharmacy holding the relevant authorization. We confirm the route in writing before taking an order. We supply worldwide wherever a lawful route exists for the product and the buyer. Every country is assessed on request, and where a market restricts a product class the route is assessed case by case and confirmed in writing.

Supplier qualification is the pharmacy's job

We supply documents. The pharmacy decides whether they are sufficient. A typical qualification file includes the following.

Qualification step What we can supply What the pharmacy does
Identify the manufacturer The manufacturing site named in the lot documents Check the site in FDA's establishment registration database
Review the certificate Certificate of analysis naming the testing laboratory Compare results with the pharmacy's own specification
Confirm origin and custody Origin statement, and a lot origin file for USA-Synthesized lots Check that lot numbers and sites agree across documents
Test incoming material Lot number and method information on request Run identity and any other tests required by its procedures
Assess suitability for sterile compounding Endotoxin and sterility results where reported Apply USP <797> and its own release testing
Keep records Lot documents and written route confirmation File them with the compounding record for each batch

The peptide API supplier checklist lists the questions to put to any supplier. For USA-Synthesized lots, the lot origin file names the synthesis site and the fill-and-finish site and discloses imported inputs.

How pharmacy accounts work

The path is apply, verification, quote, order. There are no public prices.

  • Evaluation order: stock-list items from US$2,500, once per account.
  • First production order: made-to-order product from US$10,000. Price is set by order value in four bands: under US$10,000; US$10,000 to US$20,000; US$20,000 to US$30,000; and US$30,000 and over, which carries the lowest price.
  • Supply program: accounts in the top band can agree a forward schedule with reserved capacity and reserved lots.

Every order is prepaid by bank wire or ACH. Stock-list items leave in 2 to 5 business days, and most product is made to order in about 3 weeks. A reserved lot is useful to a pharmacy because each new API lot triggers receiving tests and a formula recalculation. Fewer lot changes mean fewer of both. Conditions are in the trade terms.

What we need from a pharmacy at application

Item Why we ask
Pharmacy legal name and registered address To verify the business
State pharmacy license number and expiry date To confirm a current license
Pharmacist in charge, with contact details To have an accountable licensed contact
Whether the pharmacy operates under 503A, or is a registered 503B facility To understand which requirements the buyer works under
API items and expected quantities To quote by lot
Supplier qualification questionnaire, if the pharmacy uses one To return the documents the pharmacy needs
Ship-to address matching the licensed premises To deliver only to the licensed site

Apply through the application page.

Frequently asked questions

Do you sell compounded peptide products to pharmacies?

No. We sell bulk API powder to licensed pharmacies and licensed manufacturers. We do not compound, and we do not sell finished compounded drugs, prefilled units or patient-labeled product. Compounding, sterilization, release testing and dispensing are carried out by the pharmacy under its own license.

What does the October 2026 HHS draft policy say about peptide compounding?

As of November 2026, a draft enforcement-discretion policy published on 30 October 2026 addresses 503A compounding of BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. Among other conditions, it expects API from an FDA-registered manufacturer with a certificate of analysis identifying the manufacturing site. It is a draft, not an approval.

Does the draft policy apply to 503B outsourcing facilities?

No. The draft concerns compounding by 503A pharmacies for identified patients on prescription. It does not cover 503B outsourcing facilities, which are subject to separate requirements. Because it is a draft, its terms may change, and pharmacies should confirm their position with counsel and their state board.

Is an FDA-registered manufacturer the same as an FDA-approved one?

No. Establishment registration is a listing requirement. It is not an approval of the site or its products, and it does not by itself prove compliance with current good manufacturing practice. A pharmacy should check registration and then carry out its own qualification of the manufacturer and the supplier.

Can a pharmacy use research-grade vials for compounding?

No. Research-grade product is for laboratory research by verified institutions; not for human or veterinary use. As of November 2026, several state boards of pharmacy have said that research-labeled product cannot be used in patient care. Pharmacies are quoted bulk API powder only.

What will a pharmacy receive with each API lot?

A certificate of analysis that names the testing laboratory and reports identity, purity and peptide content, with endotoxin and sterility where relevant, plus an origin statement. USA-Synthesized lots include a lot origin file naming the synthesis site. The pharmacy should also test incoming material under its own procedures.

Is your bulk API powder sterile?

Bulk API powder should be handled as a non-sterile bulk substance unless the certificate for that lot reports a sterility result. Where endotoxin has been tested, the result and limit are shown. The pharmacy is responsible for sterilization and for release testing of anything it compounds.

Open a trade account

Tell us what you buy and where you ship. We verify your business, confirm the lawful route in writing and send a quote.

Apply for a trade account